Pharma Trade Group Calls for More Minorities in Clinical Trials
New America Media, News Report, Viji Sundaram, Posted: Mar 08, 2012
CHICAGO – Communities most impacted by diabetes, heart disease and cancer are also the least likely to be enrolled in clinical trials, making it difficult for the U.S. pharmaceutical industry to develop effective drugs to treat them.
“Different ethnicities metabolize drugs in a different way,” noted Salvatore Alesci, vice president of scientific affairs at PhRMA (Pharmaceutical Research & Manufacturers of America), as he explained to ethnic media representatives here March 1 why there’s a need to have wider representation in the clinical trial pool.
PhRMA, which represents the country’s leading pharmaceutical research and biotechnology companies that are developing medicines so patients can live longer and healthier, is looking to ethnic media outlets throughout Chicago for help in informing their audiences about the critical need to boost participation in drug trials as a way to reduce health disparities. Currently, minorities are still a minority in clinical trials. Read more